Browsing Tag
Nuvec
2 posts
Thalia Therapeutics (AIM: THAT) completes Sanmirna acquisition to add Phase 1 AML asset
Thalia Therapeutics has completed its acquisition of Sanmirna Therapeutics, adding the Phase 1 miRisten programme for relapsed or refractory acute myeloid leukaemia. The deal accelerates Thalia’s transition into clinical-stage RNA therapeutics, but more than doubles its share count and leaves future value dependent on safety data, early biological evidence and further financing.
Thalia Therapeutics (AIM: THAT) shares jump 17% as Sanmirna deal adds Phase 1 AML asset
Thalia Therapeutics has agreed to acquire Sanmirna Therapeutics and its Phase 1 acute myeloid leukaemia drug miRisten, while raising £2.75 million to fund clinical data expected in 2027.